We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

ORTHO CLINICAL DIAGNOSTICS

Ortho Clinical Diagnostics is a global provider of in vitro diagnostics, including testing platforms and clinical ass... read more Featured Products: More products

Download Mobile App





Ortho Clinical Diagnostics Highlights Immunodiagnostics at Clinical Expo

By LabMedica International staff writers
Posted on 03 Aug 2017
Print article
Image: The VITROS NephroCheck test (Photo courtesy of Ortho Clinical Diagnostics).
Image: The VITROS NephroCheck test (Photo courtesy of Ortho Clinical Diagnostics).
Ortho Clinical Diagnostics (Raritan, NJ, USA) was among over 750 exhibitors who displayed pioneering diagnostic technology, including the latest in mobile health, molecular diagnostics, mass spectrometry, point-of-care, and automation at the 69th AACC Annual Scientific Meeting & Clinical Lab Expo, the world’s largest exposition for clinical laboratory products and services.

Ortho’s in vitro diagnostics products and services for the clinical laboratory and immunohematology communities include blood typing products, sophisticated testing technologies, automation, information management and interpretation tools. At the 2017 AACC Clinical Lab Expo held at the San Diego Convention Center from August 1-3, Ortho presented 10 scientific posters highlighting its focus on immunodiagnostics, with discussions on acute kidney injury (AKI), insulin and infectious diseases.

The products on display in Ortho's booth at AACC 2017 included VITROS 3600 Immunodiagnostic Systems, VITROS 4600 Chemistry Systems, VITROS 5600 Integrated Systems, VITROS Automation Solutions, and the ORTHO VISION and ORTHO VISION Max Analyzers. The company also highlighted the NephroCheck test, a risk assessment tool for predicting AKI.

Visitors to Ortho's booth were able to see what is possible in a re-imagined lab and make tangible connections between the work accomplished in the lab and patients' wellbeing. The company’s R&D team shared its vision for the future of in vitro diagnostics in its Innovation Lab. The attendees were able to test their skills using real-time dashboard tools and also learned more about working with medical practitioners to help improve cardiac outcomes and help reduce the severity of AKI.

“AACC is a wonderful opportunity for us to engage with members of the lab community and hear their feedback on our products, both current and in development,” said Alex Socárras, chief commercial officer for Ortho.

Gold Supplier
SARS-CoV-2 qRT-PCR IVD Reagent Kit
SARS-CoV-2 qRT-PCR Dx Kit (CE-IVD)
New
Portable Tube Luminometer
Junior LB 9509
New
Electrolyte Analyzer
EXIAS
New
Tube Handler
BioMicroLab XL20

Print article
IIR Middle East

Channels

Molecular Diagnostics

view channel
Illustration

Point-of-Care Lateral Flow Test Detects Bladder Cancer Using Urine Sample within Minutes

A breakthrough diagnostics platform uses a multiplexed lateral flow assay that detects 10 bladder cancer biomarkers from a urine sample in either laboratory or point-of-care settings. SCIENION (Berlin,... Read more

Hematology

view channel
Image: Bone marrow aspirate from a patient with Acute Myeloid Leukemia: Blasts are the predominant population and have a high nuclear to cytoplasmic ratio and generally lack granules. (Photo courtesy of Professor Peter G. Maslak, MD)

Cord Blood and Matched Related Donor Transplantation Compared in Acute Myeloid Leukemia

The prognosis of primary refractory and relapsed acute myeloid leukemia is poor, with a five-year overall survival of less than 10%. Allogeneic hematopoietic stem cell transplantation (HSCT) is the only... Read more

Industry

view channel
Illustration

Global Immunofluorescence Assay (IFA) Market to Surpass USD 4 Billion by 2028 Due to Growing Burden of Infectious Diseases

The global immunofluorescence assay (IFA) market is expected to reach USD 4.01 billion by 2028, driven by the increasing global healthcare burden of chronic and infectious diseases, rising application... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.